RUNX2 and plasma cell myeloma: In MM, RUNX2 derived from myeloma cells facilitates tumor development through Akt/β-catenin/survivin signaling and upregulates the expression of multiple metastasis-related genes, which might be responsible for myeloma bone resorption [20].